Update on the role of ipilimumab in melanoma and first data on new combination therapies
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Update on the role of ipilimumab in melanoma and first data on new combination therapies
Authors
Keywords
-
Journal
CURRENT OPINION IN ONCOLOGY
Volume 25, Issue 2, Pages 166-172
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2013-01-10
DOI
10.1097/cco.0b013e32835dae4f
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Melanoma as a model tumour for immuno-oncology
- (2012) M. Maio ANNALS OF ONCOLOGY
- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
- (2012) Richard C. Koya et al. CANCER RESEARCH
- Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012
- (2012) Claus Garbe et al. EUROPEAN JOURNAL OF CANCER
- Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study)
- (2012) C. Lebbe et al. EUROPEAN JOURNAL OF CANCER
- Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
- (2012) Alexander M.M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
- (2012) Anna Maria Di Giacomo et al. LANCET ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thanks to referees 2011
- (2011) ANNALS OF ONCOLOGY
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
- (2011) Poulam M. Patel et al. EUROPEAN JOURNAL OF CANCER
- Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
- (2011) Alexander M.M. Eggermont et al. EUROPEAN JOURNAL OF CANCER
- Prognosis in Patients With Sentinel Node–Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria
- (2011) Augustinus P.T. van der Ploeg et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma
- (2011) Valerie P. Grignol et al. JOURNAL OF IMMUNOTHERAPY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
- (2010) A. A. Sarnaik et al. CLINICAL CANCER RESEARCH
- Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies—EORTC 18991
- (2010) Marna G. Bouwhuis et al. JOURNAL OF CLINICAL ONCOLOGY
- Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases
- (2010) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Endpoints for Cancer Immunotherapy Trials
- (2010) A. Hoos et al. JNCI-Journal of the National Cancer Institute
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Introduction to Immunologic Checkpoints for Cancer Treatment: From Scientific Rationale to Clinical Application
- (2010) Michele Maio SEMINARS IN ONCOLOGY
- Anti–CTLA-4 Antibody Adjuvant Therapy in Melanoma
- (2010) Alexander M.M. Eggermont et al. SEMINARS IN ONCOLOGY
- The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications
- (2010) Anna Maria Di Giacomo et al. SEMINARS IN ONCOLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon
- (2009) Marna G. Bouwhuis et al. JNCI-Journal of the National Cancer Institute
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients
- (2008) Alexander C. J. van Akkooi et al. ANNALS OF SURGERY
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- (2008) Alexander MM Eggermont et al. LANCET
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started